TherapeuticsMD Inc  

(Public, NYSEMKT:TXMD)   Watch this stock  
Find more results for TXMD
7.12
-0.12 (-1.66%)
Apr 24 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 7.12 - 7.32
52 week 3.42 - 7.49
Open 7.26
Vol / Avg. 774,967.00/1.75M
Mkt cap 1.22B
P/E     -
Div/yield     -
EPS -0.36
Shares 171.72M
Beta 4.66
Inst. own 59%
May 7, 2015
TherapeuticsMD Inc at Deutsche Bank Health Care Conference - 11:20AM EDT - Add to calendar
May 5, 2015
Q1 2015 TherapeuticsMD Inc Earnings Call - 4:30PM EDT - Add to calendar
May 5, 2015
Q1 2015 TherapeuticsMD Inc Earnings Release - 4:00PM EDT - Add to calendar
Mar 10, 2015
Q4 2014 TherapeuticsMD Inc Earnings Call
Mar 10, 2015
Q4 2014 TherapeuticsMD Inc Earnings Release
Mar 4, 2015
TherapeuticsMD Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -382.90% -360.82%
Operating margin -383.20% -359.65%
EBITD margin - -359.30%
Return on average assets -97.82% -89.54%
Return on average equity -116.78% -105.19%
Employees 100 -
CDP Score - -

Address

6800 Broken Sound Pkwy NW Fl 3
BOCA RATON, FL 33487-2721
United States - Map
+1-561-9611911 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TherapeuticsMD Inc. is women�s health care product company engaged in creating and commercializing products targeted for women. The Company is focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The Company has obtained the United States Food and Drug Administration (FDA), approval of its Investigational New Drug (IND), applications to conduct clinical trials for four of its hormone therapy drug candidates: TX 12-001HR, the Company�s oral combination of progesterone and estradiol; TX 12-002HR, its oral progesterone alone; TX 12-003HR, the Company�s oral estradiol alone; and TX 12-004HR, its suppository estradiol alone.

Officers and directors

Tommy G. Thompson J.D. Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
John C. K. Milligan IV President, Secretary, Director
Age: 51
Bio & Compensation  - Reuters
Robert G. Finizio Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
Daniel A. Cartwright Chief Financial Officer, Vice President - Finance, Treasurer
Age: 56
Bio & Compensation  - Reuters
Mitchell L. Krassan Executive Vice President, Chief Strategy Officer
Age: 48
Bio & Compensation  - Reuters
Joel S. Krasnow M.D., Chief Scientific Officer, Head - Regulatory Department
Bio & Compensation  - Reuters
Brian Bernick M.D. Chief Clinical Officer, Director
Age: 45
Bio & Compensation  - Reuters
Sebastian Mirkin M.D. Chief Medical Officer
Bio & Compensation  - Reuters
Cooper C. Collins Independent Director
Age: 35
Bio & Compensation  - Reuters
Robert V. LaPenta Jr Independent Director
Age: 68
Bio & Compensation  - Reuters